Advertisement

CNS Drugs

, Volume 33, Issue 12, pp 1147–1154 | Cite as

Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential

  • Lindsay Fox
  • Lewis S. NelsonEmail author
Current Opinion

Abstract

Patients experiencing the consequences of opioid use often present to the emergency department (ED) at times of crisis, such as following overdose or when in withdrawal. This highlights the important role of the ED in recognizing opioid use disorder and engaging these patients into ongoing treatment. Given the limited ability of the healthcare system to provide timely addiction treatment, initiation of therapy in the ED, with referral to long-term care, is associated with improved outcomes. The primary evidence-based treatment used in EDs for this indication is buprenorphine. Although clinicians may find the initiation of buprenorphine therapy daunting, it is straightforward and well-tolerated, and many of the barriers are surmountable. This article addresses these barriers, which include stigma, complicated pharmacology, and confusing regulations, and provides a basis for the use of buprenorphine in acute care clinical practice.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to prepare this manuscript.

Conflict of interest

Lindsay Fox and Lewis S. Nelson have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419–27.  https://doi.org/10.15585/mmwr.mm675152e1.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349–58.  https://doi.org/10.15585/mmwr.mm6712a1.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Belzak L, Halverson J. Evidence synthesis—the opioid crisis in Canada: a national perspective. Health Promot Chronic Dis Prev Can. 2018;38(6):224–33.  https://doi.org/10.24095/hpcdp.38.6.02.CrossRefPubMedGoogle Scholar
  4. 4.
    Goodman-Meza D, Medina-Mora ME, Magis-Rodríguez C, Landovitz RJ, Shoptaw S, Werb D. Where is the opioid use epidemic in mexico? A cautionary tale for policymakers south of the US–Mexico border. Am J Public Health. 2019;109(1):73–82.  https://doi.org/10.2105/AJPH.2018.304767.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36(1):559–74.  https://doi.org/10.1146/annurev-publhealth-031914-122957.CrossRefPubMedGoogle Scholar
  6. 6.
    Canadian Pain Society. Accreditation pain standard: Making It Happen! November 2005. https://cdn.ymaws.com/www.canadianpainsociety.ca/resource/resmgr/docs/accreditation_manual.pdf. Accessed 29 Aug 2019.
  7. 7.
    FDA Center for Drug Evaluation and Research. Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse. FDA. 2019. http://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-opioid-misuse-and-abuse. Accessed 30 Aug 2019.
  8. 8.
    Guy GP, Zhang K, Bohm MK, et al. Vital SIGNS: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697–704.  https://doi.org/10.15585/mmwr.mm6626a4.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016;387(10028):1644–56.  https://doi.org/10.1016/S0140-6736(16)00161-6.CrossRefPubMedGoogle Scholar
  10. 10.
    Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–1492.Google Scholar
  11. 11.
    Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Understanding the Epidemic | Drug Overdose | CDC Injury Center. 2019. https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed 28 Aug 2019.
  12. 12.
    Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019.  https://doi.org/10.1016/j.drugpo.2019.01.020.CrossRefPubMedGoogle Scholar
  13. 13.
  14. 14.
    Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addict Abingdon Engl. 2009;104(7):1193–200.  https://doi.org/10.1111/j.1360-0443.2009.02627.x.CrossRefGoogle Scholar
  15. 15.
    Dupouy J, Palmaro A, Fatséas M, et al. Mortality associated with time in and out of buprenorphine treatment in french office-based general practice: a 7-year cohort study. Ann Fam Med. 2017;15(4):355–8.  https://doi.org/10.1370/afm.2098.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.CrossRefGoogle Scholar
  17. 17.
    Fox LM, Hoffman RS, Vlahov D, Manini AF. Risk factors for severe respiratory depression from prescription opioid overdose. Addict Abingdon Engl. 2017.  https://doi.org/10.1111/add.13925.CrossRefGoogle Scholar
  18. 18.
    Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–80.  https://doi.org/10.1038/clpt.1994.71.CrossRefPubMedGoogle Scholar
  19. 19.
    Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137(6):501–4.CrossRefGoogle Scholar
  20. 20.
    Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104(6):993–9.  https://doi.org/10.1111/j.1360-0443.2009.02549.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137.  https://doi.org/10.7326/M17-3107.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.  https://doi.org/10.1016/S0140-6736(17)32812-X.CrossRefPubMedGoogle Scholar
  23. 23.
    Murphy SM, McCollister KE, Leff JA, et al. Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse. Ann Intern Med. 2019;170(2):90.  https://doi.org/10.7326/M18-0227.CrossRefPubMedGoogle Scholar
  24. 24.
    D’Onofrio G, McCormack RP, Hawk K. Emergency departments—a 24/7/365 option for combating the opioid crisis. N Engl J Med. 2018;379(26):2487–90.  https://doi.org/10.1056/NEJMp1811988.CrossRefPubMedGoogle Scholar
  25. 25.
    Kestler A, Wale J, Allan M. The time for emergency department opioid agonist therapy is now: “A BC perspective”. CJEM. 2019;21(4):443–5.  https://doi.org/10.1017/cem.2019.368.CrossRefPubMedGoogle Scholar
  26. 26.
    Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019;73(5):481–7.  https://doi.org/10.1016/j.annemergmed.2018.11.032.CrossRefPubMedGoogle Scholar
  27. 27.
    Weiss AJ, Heslin KC. Payers of Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2010 and 2015: Statistical Brief #239. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006. http://www.ncbi.nlm.nih.gov/books/NBK519368/. Accessed 28 Mar 2019.
  28. 28.
    Weiner SG, Baker O, Bernson D, Schuur JD. 402 one-year mortality of opioid overdose victims who received naloxone by emergency medical services. Ann Emerg Med. 2017;70(4):S158.  https://doi.org/10.1016/j.annemergmed.2017.07.281.CrossRefGoogle Scholar
  29. 29.
    Doran KM, Raja AS, Samuels EA. Opioid overdose protocols in the emergency department: are we asking the right questions? Ann Emerg Med. 2018;72(1):12–5.  https://doi.org/10.1016/j.annemergmed.2018.05.024.CrossRefPubMedGoogle Scholar
  30. 30.
    Scheuermeyer FX, DeWitt C, Christenson J, et al. Safety of a Brief emergency department observation protocol for patients with presumed fentanyl overdose. Ann Emerg Med. 2018;72(1):1-8.e1.  https://doi.org/10.1016/j.annemergmed.2018.01.054.CrossRefPubMedGoogle Scholar
  31. 31.
    D’Onofrio G, Chawarski MC, O’Connor PG, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention. J Gen Intern Med. 2017;32(6):660–6.  https://doi.org/10.1007/s11606-017-3993-2.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bernstein SL, D’Onofrio G. Screening, treatment initiation, and referral for substance use disorders. Addict Sci Clin Pract. 2017;12(1):18.  https://doi.org/10.1186/s13722-017-0083-z.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636.  https://doi.org/10.1001/jama.2015.3474.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Srivastava A, Kahan M, Njoroge I, Sommer LZ. Buprenorphine in the emergency department: randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal. Can Fam Physician Med Fam Can. 2019;65(5):e214–20.Google Scholar
  35. 35.
    Volpe DA, Tobin GAM, Mellon RD, et al. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59(3):385–90.  https://doi.org/10.1016/j.yrtph.2010.12.007.CrossRefPubMedGoogle Scholar
  36. 36.
    Woo J, Bhalerao A, Bawor M, et al. “Don’t judge a book by its cover”: a qualitative study of methadone patients’ experiences of stigma. Subst Abuse Res Treat. 2017;11:117822181668508.  https://doi.org/10.1177/1178221816685087.CrossRefGoogle Scholar
  37. 37.
    Elliott L, Bennett AS, Wolfson-Stofko B. Life after opioid-involved overdose: survivor narratives and their implications for ER/ED interventions. Addiction. 2019.  https://doi.org/10.1111/add.14608.CrossRefPubMedGoogle Scholar
  38. 38.
    Harris J, McElrath K. Methadone as social control: institutionalized stigma and the prospect of recovery. Qual Health Res. 2012;22(6):810–24.  https://doi.org/10.1177/1049732311432718.CrossRefPubMedGoogle Scholar
  39. 39.
    Anstice S, Strike CJ, Brands B. Supervised methadone consumption: client issues and stigma. Subst Use Misuse. 2009;44(6):794–808.  https://doi.org/10.1080/10826080802483936.CrossRefPubMedGoogle Scholar
  40. 40.
    Skewes MC, Gonzalez VM. The Biopsychosocial Model of Addiction. In: Principles of Addiction. Amsterdam: Elsevier; 2013. p. 61–70.  https://doi.org/10.1016/b978-0-12-398336-7.00006-1.CrossRefGoogle Scholar
  41. 41.
    Mendiola CK, Galetto G, Fingerhood M. An exploration of emergency physicians’ attitudes toward patients with substance use disorder. J Addict Med. 2018;12(2):132–5.  https://doi.org/10.1097/ADM.0000000000000377.CrossRefPubMedGoogle Scholar
  42. 42.
    Im DD, Chary A, Condella A, et al. 121 emergency providers’ attitudes towards opioid use disorder and emergency department-initiated buprenorphine treatment: a mixed-methods study. Ann Emerg Med. 2018;72(4):S52.  https://doi.org/10.1016/j.annemergmed.2018.08.126.CrossRefGoogle Scholar
  43. 43.
    Substance Abuse and Mental Health Services Administration. Special Circumstances for Providing Buprenorphine. 2019. https://www.samhsa.gov/medication-assisted-treatment/legislation-regulations-guidelines/special. Accessed 14 Apr 2019.
  44. 44.
    Samuels EA, D’Onofrio G, Huntley K, et al. A quality framework for emergency department treatment of opioid use disorder. Ann Emerg Med. 2019;73(3):237–47.  https://doi.org/10.1016/j.annemergmed.2018.08.439.CrossRefPubMedGoogle Scholar
  45. 45.
    Patil D, Andry T. Molding young minds: the importance of residency training in shaping residents’ attitudes toward substance use disorders: residency training shaping attitudes. Am J Addict. 2017;26(1):80–2.  https://doi.org/10.1111/ajad.12484.CrossRefPubMedGoogle Scholar
  46. 46.
    Livingston JD, Milne T, Fang ML, Amari E. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review: reducing substance use-related stigma. Addiction. 2012;107(1):39–50.  https://doi.org/10.1111/j.1360-0443.2011.03601.x.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Wakeman SE, Kanter GP, Donelan K. Institutional substance use disorder intervention improves general internist preparedness, attitudes, and clinical practice. J Addict Med. 2017;11(4):308–14.  https://doi.org/10.1097/ADM.0000000000000314.CrossRefPubMedGoogle Scholar
  48. 48.
    Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend. 2007;90(2–3):261–9.  https://doi.org/10.1016/j.drugalcdep.2007.04.006.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Vogel M, Hämmig R, Kemter A, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the “Bernese method&rdquo. Subst Abuse Rehabil. 2016;7:99–105.  https://doi.org/10.2147/SAR.S109919.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Emergency Medicine, Division of Medical ToxicologyRutgers New Jersey Medical SchoolNewarkUSA

Personalised recommendations